We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention.
Transplantation Proceedings 1998 September
Long-term immunosuppression necessary for transplantation places susceptible individuals with chronic actinic damage at increased risk for the development of aggressive skin cancers. Candidates for transplantation should be evaluated for the risk factors associated with skin cancer. Those who are at risk should be educated in the measures for and the importance of diligent UVR protection, frequent self-examination of the skin, and regular dermatologic evaluation to minimize the morbidity and morality from NMSC. Identified skin cancers (especially SCC) should be treated aggressively. Individuals who are actively developing many cancers may be candidates for retinoid chemoprevention.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app